A clinical thread for a change - appreciate if the funding discussion be kept it those threads and not derail or take this one off-topic. Besides, IMO there is Nothing to be gained there - (ATM).
So its clear Mix & Go is facilitating tests on very small volumes of blood. It would timley for the Investment market to get a clearer picture on say, Anteo's progress in test development in the Rat & Mice based R&D market. Faster, smaller, cheaper/incresed sensitivity - so where is eBioscience/Affymetrix on this page? Is there any connection with the Birmingham/San Diago based (yes AT you kept a close travel itinery watch on Geoff), The Binding Site group and their ties to Flow Cytometry and eBioscience? Would the DIAsource M&A now run interference with other potential collaborations?
Until corrected or company updated, I would have to consider the previously mentioned royalty revenue stream to be from eBioscience.
R&D arena Rat leverage
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $50.57M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.2¢ | 2.1¢ | $45.93K | 2.187M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 93000 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 595988 | 5 |
View Market Depth
| Last trade - 10.22am 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
2.1¢ |
Change
0.000 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 2.1¢ | 2.1¢ | 2.1¢ | 1064208 | ||
| Last updated 10.22am 08/05/2024 ? | |||||
| ADO (ASX) Chart |